Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent

25-May-2012 - USA

Alnylam Pharmaceuticals, Inc. and Plant Bioscience Limited (PBL) announced  that they have entered into a licensing agreement.  PBL has granted Alnylam a world-wide, non-exclusive license to the Baulcombe patent (U.S. Patent No. 8,097,710) for use in the field of human therapeutics.  Financial terms were not disclosed.

“We are pleased to expand our leading IP estate with a license to the Baulcombe patent,” said Laurence Reid, Ph.D., Senior Vice President and Chief Business Officer of Alnylam.  “Alnylam continues to leverage its patent estate for the advancement of innovative medicines to patients and to enable the entire RNAi therapeutics field, with over 30 license agreements formed to date.”

U.S. Patent No. 8,097,710 issued in January 2012, and is the most recently issued patent in PBL’s IP estate in short RNAs derived from the seminal work of Prof David Baulcombe and Dr Andrew Hamilton, at The Sainsbury Laboratory (Norwich, UK).

Other news from the department research and development

Most read news

More news from our other portals

Last viewed contents

QIAGEN and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography

U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test

Global Pharmaceutical companies expect hard price competition in the rising Biosimilars segment - Bi-annual survey among more than 80 executives from globally active pharmaceutical companies based in 16 countries and spread over four continents

Metobolomics uncovers key indicators of nonalcoholic fatty liver disease - Impaired oxidation in liver associated with progression to NASH

Converting carbon dioxide into useful chemicals with the help of bacteria and solar power - How electrolysis and fermentation can be combined in one system

Converting carbon dioxide into useful chemicals with the help of bacteria and solar power - How electrolysis and fermentation can be combined in one system

Agilent Technologies Presents Thought Leader Award to Lipidomics Expert Dr. Jules Griffin - Cambridge Researcher to Further Studies of Obesity, Fatty Liver Disease

3D images display plant organs down to the smallest detail - Intelligent software for a better understanding of plant tissue development

3D images display plant organs down to the smallest detail - Intelligent software for a better understanding of plant tissue development

Antibiotic treatment increases the severity of asthma in young mice

Children with rare, incurable brain disease improve after gene therapy

'An underutilized tool:' UV-LED lights can kill coronaviruses and HIV with the flip of a switch - A Toronto-based start-up company that partnered for the study, is developing unique UV-LED lighting modules

'An underutilized tool:' UV-LED lights can kill coronaviruses and HIV with the flip of a switch - A Toronto-based start-up company that partnered for the study, is developing unique UV-LED lighting modules

Research ushers in new era of boutique chocolate

New, old science combine to make faster medical test